Since the discovery of leptin in 1994 and the delineation of its anorectic effects, there has been a considerable interest in transforming these insights into efficacious anti-obesity pharmacotherapy. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.